113 related articles for article (PubMed ID: 32251559)
1. [Ki67 in the prognosis of prostate cancer].
Huang T; Liu JJ; Zhang JW; Zhu ZC; Wang T; Cai L; Chen ZQ
Zhonghua Nan Ke Xue; 2019 Dec; 25(12):1088-1092. PubMed ID: 32251559
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.
Tretiakova MS; Wei W; Boyer HD; Newcomb LF; Hawley S; Auman H; Vakar-Lopez F; McKenney JK; Fazli L; Simko J; Troyer DA; Hurtado-Coll A; Thompson IM; Carroll PR; Ellis WJ; Gleave ME; Nelson PS; Lin DW; True LD; Feng Z; Brooks JD
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):264-70. PubMed ID: 27136741
[TBL] [Abstract][Full Text] [Related]
3. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
[TBL] [Abstract][Full Text] [Related]
5. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
6. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
[TBL] [Abstract][Full Text] [Related]
8. Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy.
He J; Che B; Li P; Li W; Huang T; Chen P; Liu M; Li G; Zhong S; Tang K
Front Surg; 2023; 10():1140883. PubMed ID: 37091270
[TBL] [Abstract][Full Text] [Related]
9. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.
Gunia S; Albrecht K; Koch S; Herrmann T; Ecke T; Loy V; Linke J; Siegsmund M; May M
World J Urol; 2008 Jun; 26(3):243-50. PubMed ID: 18392627
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
11. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
Hung AY; Levy L; Kuban DA
Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic characteristics and prognosis of early onset prostate cancer].
Wang Y; Du SJ; Zhang JX; He HY
Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):373-377. PubMed ID: 28591982
[No Abstract] [Full Text] [Related]
13. Prognostic value of transformer 2β expression in prostate cancer.
Diao Y; Wu D; Dai Z; Kang H; Wang Z; Wang X
Int J Clin Exp Pathol; 2015; 8(6):6967-73. PubMed ID: 26261585
[TBL] [Abstract][Full Text] [Related]
14. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
16. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
17. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
[TBL] [Abstract][Full Text] [Related]
18. [Epidemiological and clinicopathological characteristics of prostate cancer in Hunan].
Zou B; Long Y; Yang ZM; Gao RS; Lin QF; Dai XJ; Yi G; Wang QZ; Zhou Q; Zhang XB
Zhonghua Nan Ke Xue; 2022 Sep; 28(9):786-791. PubMed ID: 37839003
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
Hammarsten P; Josefsson A; Thysell E; Lundholm M; Hägglöf C; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Granfors T; Wikström P; Bergh A
Mod Pathol; 2019 Sep; 32(9):1310-1319. PubMed ID: 30980038
[TBL] [Abstract][Full Text] [Related]
20. Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells.
Nikoleishvili D; Pertia A; Trsintsadze O; Gogokhia N; Managadze L; Chkhotua A
Int Urol Nephrol; 2008; 40(4):953-9. PubMed ID: 18317945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]